^
Association details:
| Biomarker: | EGFR P719A + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor + PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
383 - Efficacy of immune checkpoint inhibitors in lung cancer patients with EGFR P719A mutation: A case report
Published date:
03/10/2021
Excerpt:
A 52-year-old male never-smoker...The tumor was positive for EGFR, EGFR P719A mutation. The PD-L1 expression have been tested by FDA-approved 22C3 antibodies, and PD-L1 expression level of 95%. The patients received anti-PD-1 combination treatment. He has reached partial response (PR) after 4 cycle treatment. After ten months, he has the opportunity to receive the operation....NSCLC patients harboring sensitizing oncogenic mutations may potentially benefit from anti-PD-1/L1 especially for those with positive indicators of immunotherapy with strong positive PD-L1 expression.
